Alimera Sciences (ALIM) Stock Forecast, Price Target & Predictions
ALIM Stock Forecast
Alimera Sciences stock forecast is as follows: an average price target of $5.75 (represents a 3.79% upside from ALIM’s last price of $5.54) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.
ALIM Price Target
The average price target for Alimera Sciences (ALIM) is $5.75 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $5.50. This represents a potential 3.79% upside from ALIM's last price of $5.54.
ALIM Analyst Ratings
According to 9 Wall Street analysts, Alimera Sciences's rating consensus is 'Hold'. The analyst rating breakdown for ALIM stock is 1 'Strong Buy' (11.11%), 2 'Buy' (22.22%), 5 'Hold' (55.56%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).
Alimera Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 25, 2024 | Yi Chen | H.C. Wainwright | $6.00 | $5.54 | 8.30% | 8.30% |
| Jun 24, 2024 | Chase Knickerbocker | Craig-Hallum | $5.50 | $5.54 | -0.72% | -0.72% |
| Jul 28, 2022 | - | H.C. Wainwright | $9.00 | $5.49 | 63.93% | 62.45% |
| May 10, 2022 | - | H.C. Wainwright | $8.00 | $5.05 | 58.42% | 44.40% |
The latest Alimera Sciences stock forecast, released on Jun 25, 2024 by Yi Chen from H.C. Wainwright, set a price target of $6.00, which represents a 8.30% increase from the stock price at the time of the forecast ($5.54), and a 8.30% increase from ALIM last price ($5.54).
Alimera Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $5.75 |
| Last Closing Price | $5.54 | $5.54 | $5.54 |
| Upside/Downside | -100.00% | -100.00% | 3.79% |
In the current month, the average price target of Alimera Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alimera Sciences's last price of $5.54. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 25, 2024 | Alliance Global Partners | Buy | Neutral | Downgrade |
| Jun 25, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Jun 24, 2024 | Craig-Hallum | - | Hold | Downgrade |
| Jun 12, 2023 | Raymond James | - | Strong Buy | Upgrade |
| Jun 12, 2023 | Credit Suisse | - | Neutral | Downgrade |
| Jun 12, 2023 | Morgan Stanley | - | Underweight | Downgrade |
| Jun 12, 2023 | BMO Capital | - | Market Perform | Downgrade |
| Jun 12, 2023 | Scotiabank | - | Outperform | Upgrade |
| Jun 12, 2023 | William Blair | - | Outperform | Upgrade |
| Jun 12, 2023 | Alliance Global Partners | - | Buy | Upgrade |
Alimera Sciences's last stock rating was published by Alliance Global Partners on Jun 25, 2024. The company Downgrade its ALIM rating from "Buy" to "Neutral".
Alimera Sciences Financial Forecast
Alimera Sciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $26.31M | $23.36M | $17.54M | $13.55M | $14.03M | $13.60M | $14.60M | $11.90M | $13.96M | $12.15M | $21.70M | $11.21M | $13.77M | $12.47M | $10.04M | $14.54M | $17.35M | $12.85M |
| Avg Forecast | $35.90M | $31.80M | $32.20M | $27.90M | $33.03M | $29.97M | $29.57M | $25.93M | $29.90M | $27.43M | $25.74M | $22.25M | $24.33M | $22.70M | $20.47M | $12.30M | $14.63M | $15.05M | $13.14M | $12.53M | $13.40M | $12.37M | $16.04M | $11.40M | $13.43M | $10.89M | $6.58M | $14.09M | $14.99M | $12.79M |
| High Forecast | $35.90M | $31.80M | $32.20M | $27.90M | $33.03M | $29.97M | $29.57M | $25.93M | $29.90M | $27.43M | $25.74M | $22.25M | $24.33M | $22.70M | $20.47M | $12.30M | $14.63M | $15.05M | $13.14M | $12.53M | $13.40M | $12.37M | $16.04M | $11.40M | $13.43M | $10.89M | $6.58M | $14.09M | $14.99M | $12.79M |
| Low Forecast | $35.90M | $31.80M | $32.20M | $27.90M | $33.03M | $29.97M | $29.57M | $25.93M | $29.90M | $27.43M | $25.74M | $22.25M | $24.33M | $22.70M | $20.47M | $12.30M | $14.63M | $15.05M | $13.14M | $12.53M | $13.40M | $12.37M | $16.04M | $11.40M | $13.43M | $10.89M | $6.58M | $14.09M | $14.99M | $12.79M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.03% | 0.86% | 1.10% | 0.96% | 0.90% | 1.11% | 0.95% | 1.04% | 0.98% | 1.35% | 0.98% | 1.03% | 1.15% | 1.52% | 1.03% | 1.16% | 1.00% |
Alimera Sciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $22.25M, with a low forecast of $22.25M, and a high forecast of $22.25M. ALIM's average Quarter revenue forecast represents a -15.44% decrease compared to the company's last Quarter revenue of $26.31M (Dec 23).
Alimera Sciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $3.76M | $-6.24M | $-14.17M | $-2.62M | $-1.43M | $-2.75M | $-1.30M | $-3.46M | $-2.12M | $-2.34M | $10.19M | $-1.67M | $1.01M | $1.35M | $-505.00K | $791.00K | $2.15M | $-1.16M |
| Avg Forecast | $-292.06K | $-258.70K | $-261.96K | $-226.98K | $-268.74K | $-243.79K | $-240.53K | $-210.98K | $-243.24K | $-223.16K | $-209.41K | $-4.80M | $-197.96K | $-184.67K | $-166.50K | $-3.79M | $-1.52M | $-122.41K | $-106.87K | $-3.00M | $-109.05K | $-100.64K | $-130.49K | $-1.39M | $-109.29K | $-88.61K | $-53.56K | $1.03M | $-121.98K | $-104.03K |
| High Forecast | $-292.06K | $-258.70K | $-261.96K | $-226.98K | $-268.74K | $-243.79K | $-240.53K | $-210.98K | $-243.24K | $-223.16K | $-209.41K | $-3.84M | $-197.96K | $-184.67K | $-166.50K | $-3.03M | $-1.22M | $-122.41K | $-106.87K | $-2.40M | $-109.05K | $-100.64K | $-130.49K | $-1.11M | $-109.29K | $-88.61K | $-53.56K | $1.23M | $-121.98K | $-104.03K |
| Low Forecast | $-292.06K | $-258.70K | $-261.96K | $-226.98K | $-268.74K | $-243.79K | $-240.53K | $-210.98K | $-243.24K | $-223.16K | $-209.41K | $-5.76M | $-197.96K | $-184.67K | $-166.50K | $-4.55M | $-1.83M | $-122.41K | $-106.87K | $-3.60M | $-109.05K | $-100.64K | $-130.49K | $-1.67M | $-109.29K | $-88.61K | $-53.56K | $821.17K | $-121.98K | $-104.03K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -19.01% | 33.76% | 85.12% | 0.69% | 0.93% | 22.44% | 12.20% | 1.15% | 19.41% | 23.28% | -78.05% | 1.20% | -9.26% | -15.25% | 9.43% | 0.77% | -17.58% | 11.18% |
1 analysts predict ALIM's average Quarter EBITDA for Mar 24 to be $-4.80M, with a high of $-3.84M and a low of $-5.76M. This is -227.42% lower than Alimera Sciences's previous annual EBITDA (Dec 23) of $3.76M.
Alimera Sciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-3.78M | $-1.35M | $-10.03M | $-8.30M | $-3.78M | $-5.26M | $-3.12M | $-7.76M | $-4.11M | $-4.18M | $7.57M | $-3.65M | $-977.00K | $-618.00K | $-2.55M | $-1.20M | $498.00K | $-3.14M |
| Avg Forecast | $6.53M | $3.26M | $3.26M | $-543.84K | $5.98M | $1.90M | $1.63M | $-1.36M | $1.99M | $-543.84K | $-1.99M | $-7.32M | $1.09M | $6.53M | $271.92K | $-5.79M | $-2.96M | $-21.75M | $-36.44M | $-4.57M | $-22.84M | $-28.55M | $57.65M | $-3.04M | $-2.36M | $-18.22M | $-67.98M | $-1.55M | $-16.10M | $-29.91M |
| High Forecast | $6.53M | $3.26M | $3.26M | $-543.84K | $5.98M | $1.90M | $1.63M | $-1.36M | $1.99M | $-543.84K | $-1.99M | $-5.86M | $1.09M | $6.53M | $271.92K | $-4.63M | $-2.37M | $-21.75M | $-36.44M | $-3.66M | $-22.84M | $-28.55M | $58.97M | $-2.43M | $-2.36M | $-18.22M | $-67.98M | $-1.24M | $-16.10M | $-29.91M |
| Low Forecast | $6.53M | $3.26M | $3.26M | $-543.84K | $5.98M | $1.90M | $1.63M | $-1.36M | $1.99M | $-543.84K | $-1.99M | $-8.78M | $1.09M | $6.53M | $271.92K | $-6.94M | $-3.55M | $-21.75M | $-36.44M | $-5.49M | $-22.84M | $-28.55M | $56.32M | $-3.65M | $-2.36M | $-18.22M | $-67.98M | $-1.87M | $-16.10M | $-29.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -3.48% | -0.21% | -36.88% | 1.43% | 1.28% | 0.24% | 0.09% | 1.70% | 0.18% | 0.15% | 0.13% | 1.20% | 0.41% | 0.03% | 0.04% | 0.77% | -0.03% | 0.10% |
Alimera Sciences's average Quarter net income forecast for Sep 21 is $-28.55M, with a range of $-28.55M to $-28.55M. ALIM's average Quarter net income forecast represents a -477.41% decrease compared to the company's last Quarter net income of $7.57M (Jun 21).
Alimera Sciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $14.15M | $11.55M | $10.81M | $9.97M | $9.10M | $9.86M | $9.81M | $10.09M | $10.37M | $8.56M | $8.69M | $8.23M | $8.44M | $7.38M | $7.36M | $8.85M | $10.31M | $9.56M |
| Avg Forecast | $23.32M | $20.65M | $20.91M | $18.12M | $21.46M | $19.46M | $19.20M | $16.84M | $19.42M | $17.82M | $16.72M | $12.41M | $15.80M | $14.74M | $13.29M | $9.81M | $7.47M | $9.77M | $8.53M | $7.75M | $8.71M | $8.03M | $10.42M | $6.86M | $8.73M | $7.07M | $4.28M | $11.49M | $9.74M | $8.31M |
| High Forecast | $23.32M | $20.65M | $20.91M | $18.12M | $21.46M | $19.46M | $19.20M | $16.84M | $19.42M | $17.82M | $16.72M | $14.89M | $15.80M | $14.74M | $13.29M | $11.77M | $8.96M | $9.77M | $8.53M | $9.30M | $8.71M | $8.03M | $10.42M | $8.23M | $8.73M | $7.07M | $4.28M | $13.79M | $9.74M | $8.31M |
| Low Forecast | $23.32M | $20.65M | $20.91M | $18.12M | $21.46M | $19.46M | $19.20M | $16.84M | $19.42M | $17.82M | $16.72M | $9.92M | $15.80M | $14.74M | $13.29M | $7.85M | $5.97M | $9.77M | $8.53M | $6.20M | $8.71M | $8.03M | $10.42M | $5.49M | $8.73M | $7.07M | $4.28M | $9.19M | $9.74M | $8.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.78% | 0.81% | 1.02% | 1.22% | 1.01% | 1.15% | 1.30% | 1.19% | 1.07% | 0.83% | 1.20% | 0.97% | 1.04% | 1.72% | 0.77% | 1.06% | 1.15% |
Alimera Sciences's average Quarter SG&A projection for Mar 24 is $12.41M, based on 1 Wall Street analysts, with a range of $9.92M to $14.89M. The forecast indicates a -12.31% fall compared to ALIM last annual SG&A of $14.15M (Dec 23).
Alimera Sciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 | 4 | 4 | 7 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.07 | $-0.04 | $-1.24 | $-1.18 | $-0.54 | $-0.75 | $-0.45 | $-1.11 | $-0.59 | $-0.60 | $1.03 | $-0.63 | $-0.18 | $-0.12 | $-0.51 | $-0.24 | $0.08 | $-0.60 |
| Avg Forecast | $0.12 | $0.06 | $0.06 | $-0.01 | $0.11 | $0.04 | $0.03 | $-0.03 | $0.04 | $-0.01 | $-0.04 | $-0.06 | $0.02 | $0.12 | $0.01 | $-0.52 | $-0.34 | $-0.40 | $-0.67 | $-0.74 | $-0.42 | $-0.53 | $1.06 | $-0.54 | $-0.04 | $-0.34 | $-1.25 | $-0.40 | $-0.30 | $-0.55 |
| High Forecast | $0.12 | $0.06 | $0.06 | $-0.01 | $0.11 | $0.04 | $0.03 | $-0.03 | $0.04 | $-0.01 | $-0.04 | $-0.06 | $0.02 | $0.12 | $0.01 | $-0.52 | $-0.34 | $-0.40 | $-0.67 | $-0.74 | $-0.42 | $-0.53 | $1.08 | $-0.54 | $-0.04 | $-0.34 | $-1.25 | $-0.40 | $-0.30 | $-0.55 |
| Low Forecast | $0.12 | $0.06 | $0.06 | $-0.01 | $0.11 | $0.04 | $0.03 | $-0.03 | $0.04 | $-0.01 | $-0.04 | $-0.06 | $0.02 | $0.12 | $0.01 | $-0.52 | $-0.34 | $-0.40 | $-0.67 | $-0.74 | $-0.42 | $-0.53 | $1.04 | $-0.54 | $-0.04 | $-0.34 | $-1.25 | $-0.40 | $-0.30 | $-0.55 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -3.48% | -0.35% | -248.00% | 2.29% | 1.61% | 1.88% | 0.67% | 1.49% | 1.40% | 1.14% | 0.97% | 1.17% | 4.15% | 0.36% | 0.41% | 0.61% | -0.27% | 1.09% |
According to 1 Wall Street analysts, Alimera Sciences's projected average Quarter EPS for Sep 21 is $-0.53, with a low estimate of $-0.53 and a high estimate of $-0.53. This represents a -150.97% decrease compared to ALIM previous annual EPS of $1.03 (Jun 21).
ALIM Forecast FAQ
Is Alimera Sciences a good buy?
No, according to 9 Wall Street analysts, Alimera Sciences (ALIM) is considered a 'Hold'. The rating consensus is based on 1 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of ALIM's total ratings.
What is ALIM's price target?
Alimera Sciences (ALIM) average price target is $5.75 with a range of $5.5 to $6, implying a 3.79% from its last price of $5.54. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alimera Sciences stock go up soon?
According to Wall Street analysts' prediction for ALIM stock, the company can go up by 3.79% (from the last price of $5.54 to the average price target of $5.75), up by 8.30% based on the highest stock price target, and down by -0.72% based on the lowest stock price target.
Can Alimera Sciences stock reach $8?
ALIM's average twelve months analyst stock price target of $5.75 does not support the claim that Alimera Sciences can reach $8 in the near future.
What are Alimera Sciences's analysts' financial forecasts?
Alimera Sciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $118.5M (high $118.5M, low $118.5M), average EBITDA is $-964K (high $-964K, low $-964K), average net income is $8.16M (high $8.16M, low $8.16M), average SG&A $76.97M (high $76.97M, low $76.97M), and average EPS is $0.15 (high $0.15, low $0.15). ALIM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $127.8M (high $127.8M, low $127.8M), average EBITDA is $-1.04M (high $-1.04M, low $-1.04M), average net income is $12.51M (high $12.51M, low $12.51M), average SG&A $83.01M (high $83.01M, low $83.01M), and average EPS is $0.23 (high $0.23, low $0.23).
Did the ALIM's actual financial results beat the analysts' financial forecasts?
Based on Alimera Sciences's last annual report (Dec 2023), the company's revenue was $80.75M, beating the average analysts forecast of $79.8M by 1.20%. Apple's EBITDA was $6.82M, missing the average prediction of $-4.341M by -257.01%. The company's net income was $-20.132M, missing the average estimation of $2.1M by -1058.96%. Apple's SG&A was $46.48M, missing the average forecast of $53.65M by -13.37%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.37 by 113.51%. In terms of the last quarterly report (Dec 2023), Alimera Sciences's revenue was $26.31M, beating the average analysts' forecast of $24.33M by 8.11%. The company's EBITDA was $3.76M, missing the average prediction of $-198K by -2001.39%. Alimera Sciences's net income was $-3.781M, missing the average estimation of $1.09M by -447.62%. The company's SG&A was $14.15M, missing the average forecast of $15.8M by -10.49%. Lastly, the company's EPS was $-0.0695, missing the average prediction of $0.02 by -447.50%